Format

Send to

Choose Destination
Mov Disord. 2014 Sep;29(10):1319-22. doi: 10.1002/mds.25948. Epub 2014 Jul 16.

Flt3 ligand does not differentiate between Parkinsonian disorders.

Author information

1
Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden.

Abstract

BACKGROUND:

Differential diagnosis of parkinsonian disorders is challenging because of overlapping symptoms, especially during early stages of disease. No validated biomarkers are available for early and accurate diagnosis of multiple system atrophy and other parkinsonian disorders. It has been reported that flt3 ligand levels in cerebrospinal fluid could clearly differentiate patients with Parkinson's disease from patients with multiple system atrophy, with 99% sensitivity and 95% specificity.

METHODS:

We measured flt3 ligand levels in cerebrospinal fluid of subjects with Parkinson's disease (n = 37), multiple system atrophy (n = 30), and progressive supranuclear palsy (n = 19).

RESULTS:

In our cohort, no significant difference was found in flt3 ligand levels between Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

CONCLUSIONS:

Our results suggest that cerebrospinal fluid flt3 ligand levels do not differentiate between parkinsonian disorders.

KEYWORDS:

Parkinson's disease; biomarker; flt3 ligand; multiple system atrophy; progressive supranuclear palsy

PMID:
25044107
DOI:
10.1002/mds.25948
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center